The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2026 | Treatment after progression on amivantamab in EGFR exon 20 insertion-mutated NSCLC
Chul Kim, MD, Georgetown University, Washington, DC, explores treatment options for patients with EGFR exon 20 insertion-mutated non-small cell lung cancer (NSCLC) who progress on frontline amivantamab plus chemotherapy, including sunvozertinib, datopotamab deruxtecan. This interview took place at the IASLC 2026 World Conference on Lung Cancer congress in Seoul, Republic of Korea.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
